Stay updated with breaking news from Dan Azagury. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A report by Blue Shield notes that more than half of people on weight loss medications such as Wegovy and Saxenda stop taking the drugs before they can reap the benefits
Quotable quotes heard by <em>MedPage Today</em>'s reporters
Topline results add yet another potential reason for use of dual GIP/GLP-1 receptor agonist
Patients on GLP-1 drugs like Ozempic for weight loss often gain back the pounds they shed after they stop taking them. But continuing treatment indefinitely isn't viable...
The U.S. Food and Drug Administration approved the weight-loss drug Wegovy as a treatment to reduce cardiovascular risk in adults who are overweight, the first approval of its kind.